Gastric inhibitory peptidefunction Gastric inhibitory peptide (GIP), also known as glucose-dependent insulinotropic polypeptide, is a crucial hormone produced in the upper gut that plays a significant role in regulating glucose homeostasis and insulin secretion. Originally identified for its ability to inhibit gastric acid secretion, modern research highlights its primary function as an incretin hormone, meaning it stimulates insulin release in response to nutrient intake. This dual nature, coupled with its involvement in appetite and energy balance, makes GIP a subject of considerable interest in endocrinology and metabolic research.
The most prominent function of gastric inhibitory peptide is its role as an incretin. Upon consumption of food, particularly carbohydrates and fats, specialized cells in the duodenum and upper small intestine, known as K cells, release GIP into the bloodstream. GIP then travels to the pancreas, where it acts on beta cells, significantly potentiating glucose-induced insulin secretion.2025年2月19日—GIP, also known as gastric inhibitory polypeptide, or glucose-dependent insulinotropic polypeptide, is a 42 amino acid peptide hormone ... This incretin effect is vital for efficiently managing blood glucose levels after a mealGIP, also known as gastric inhibitory polypeptide, or glucose-dependent insulinotropic polypeptide, is a 42-amino-acid peptide hormone synthesized in and .... While GIP's insulinotropic effect is potent, it is glucose-dependent, meaning it is most effective when blood glucose levels are elevated2004年12月1日—GIP may play a role in the initiation of impaired β-cell functionin first-degree relatives of type 2 diabetic patients. However, GIP action may ....
Gastric inhibitory peptide was first isolated in the early 1970s and was initially named based on its observed effect of inhibiting gastric acid secretion in animal models. This early understanding focused on its potential role in suppressing the digestive process. However, further research revealed that its influence on gastric acid is relatively modest in humans compared to its powerful stimulatory effect on insulin release.Released in response to food,GIP stimulates insulin secretion from the pancreasand also influences appetite and energy balance. It works alongside GLP-1 and ... This led to its reclassification and a broader understanding of its physiological importance, particularly in the context of nutrient absorption and glucose metabolism.
The actions of gastric inhibitory peptide are mediated through its specific receptor, the GIP receptor (GIP-R)Gastric inhibitory polypeptide (GIP) isa hormone secreted by cells in the upper small intestinethat has two main actions: it potentiates glucose-induced .... This receptor is a protein found on various cells, including pancreatic beta cells, adipocytes, and even in the central nervous system. When GIP binds to its receptor, it triggers a cascade of intracellular signaling events that ultimately lead to its physiological effects, such as increased insulin synthesis and secretion.2004年12月1日—GIP may play a role in the initiation of impaired β-cell functionin first-degree relatives of type 2 diabetic patients. However, GIP action may ... The interaction between GIP and its receptor is highly specific and forms the basis for GIP's regulatory functions.
Gastric inhibitory peptide is often discussed alongside another key incretin hormone, glucagon-like peptide-1 (GLP-1). Both GIP and GLP-1 are secreted from the intestine in response to food intake and contribute to the incretin effect.Released in response to food,GIP stimulates insulin secretion from the pancreasand also influences appetite and energy balance. It works alongside GLP-1 and ... However, they have distinct characteristics and regulatory roles. While GIP primarily stimulates insulin secretion and also influences glucagon and somatostatin release, GLP-1 has a broader range of effects, including suppressing glucagon secretion, slowing gastric emptying, and promoting satiety. The interplay between GIP and GLP-1 is complex, and research is ongoing to understand how they coordinate to regulate glucose metabolism and appetite作者：MM Wolfe·2025·被引用次数：17—Although originally named “gastric inhibitory polypeptide” on the basis of its ability to inhibit gastric acid secretion,GIPaccounts for 60% to 80% of the ....
The significant role of gastric inhibitory peptide in glucose homeostasis has made it a target for therapeutic interventions, particularly in the management of type 2 diabetes and obesity. Dual-acting agents that target both GIP and GLP-1 receptors have shown promising results in clinical trials, demonstrating substantial weight loss and improvements in glycemic control. Furthermore, GIP receptor antagonists are being investigated as potential treatments for conditions where GIP signaling might be detrimental. The ongoing research into GIP and its associated pathways holds considerable promise for developing novel strategies to combat metabolic diseases.
Join the newsletter to receive news, updates, new products and freebies in your inbox.